个人情况介绍、概览

贾丽娜，女，博士，副教授。2002年毕业于沈阳药科大学，获中药学学士学位，2005年于同校获药理学硕士学位，留校任教后赴韩国国立首尔大学进行博士课题研究，2015年获沈阳药科大学药理学博士学位。2023年晋升副教授。作为课题负责人主持了国家自然科学基金青年基金项目1项，辽宁省教育厅基本科研类面上项目1项，另外，作为项目骨干成员承担国家自然科学基金面上项目13项。目前已在Adavanced Science, Apoptosis, Cell Death & Disease, Molecular Cancer Rearch, New Journal of Chemistry等期刊发表论文10余篇。

人才称号、社会兼职等（限填10项）

1.辽宁省免疫学会药学分会第一届专业委员会秘书；

主要研究方向（限填3项）

研究方向一：抑癌蛋白与致癌蛋白间相互作用及下游靶基因变化对肿瘤生物学特性的影响

研究方向二：肿瘤耐药的分子机制及肿瘤合成致死策略研究

研究方向三：抗肿瘤药物筛选、活性评价与开发

主持、参与的科研项目（含科研获奖等情况）（限填10项）

1.AURKA/SMAD4信号通路对结直肠癌西妥昔单抗耐药的影响及分子靶向治疗研究，国家自然科学基金青年科学基金项目，基金编号81903112（负责人）

2.抑癌基因SMAD4协同致死抗肿瘤靶标的筛选和鉴定，辽宁省教育厅基本科研类面上项目，项目编号JYTMS20231367（负责人）

近年来发表代表性论文(限第一作者或通讯作者，SCI须写明影响因子)：（限填10篇）

1.Jianmin Wang#, Cheng Yang#, Huashen Xu#, Xinyu Fan#, Lina Jia#, Yang Du, Shougeng Liu, Wenjing Wang, Jie Zhang, Yu Zhang, Xiaoxue Wang, Zhongbo Liu, Jie Bao, Songping Li, Jingyu Yang, Chunfu Wu, Jing Tang, Guoliang Chen,* Lihui Wang,* The interplay between HIF-1α and EZH2 in lung cancer and dual-targeted drug therapy. Adavanced Science, 2023; doi:10.1002/advs.202303904.中科院分区一区,IF:15.1

2.Shougeng Liu, Sihong Chen, Chengfang Tang, Yingxi Zhao, Wei Cui, Lina Jia,* Lihui Wang,* The emerging therapeutic target of dynamic and reversible N6-methyladenosine modification during cancer development. Frontiers in Oocology, 2022; 26(12): 970833.中科院分区三区,IF:4.7

3.Lina Jia#, Xiaoyun Gao, Yi Fang, Haotian Zhang, Lihui Wang, Xing Tang, Jingyu Yang,* Chunfu Wu,* TM2, a novel semi-synthetic taxoid, exerts anti-MDR activity in NSCLC by inhibiting P-gp function and stabilizing microtubule polymerization. Apoptosis, 2022; 27(11-12): 1015.中科院分区二区,IF:7.2

4.Gangfeng Jiang#, Nannan Wang#, Lina Jia#, Hongli Che, Lihui Wang, Jingyu Yang, Hui Xu, Chunfu Wu,* Mingzhe Liu,* Multi-functional DNA-conjugated nanohydrogels for aptamer-directed breast cancer cell targeting. New Journal of Chemistry, 2021; 45(43): 20410.中科院分区三区,IF:3.925

5.Qifan Zhou#, Lina Jia#, Fangyu Dua, Xiaoyu Dongb, Wanyu Sunb, Lihui Wang*, Guoliang Chen*, Design, Synthesis and Biological Activities of Pyrrole-3-carboxamide Derivatives as EZH2 (Enhancer of Zeste Homologue2) Inhibitors and Anticancer Agents. New Journal of Chemistry, 2020; 44(6): 2247.中科院分区三区,IF:3.288

6.Mei Han#, Lina Jia#, Wencai Lv, Lihui Wang* and Wei Cui*, Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors. Frontiers in oncology, 2019; 27(11-12):1015.中科院分区二区,IF:4.848

7.Yuhong Sun#, Xuefei Bao#, Yong Ren#, Lina Jia#, Shenglan Zou, Jian Han, Mengyue Zhao, Mei Han, Hong Li, Qixiang Hua, Yi Fang, Jingyu Yang, Chunfu Wu, Guoliang Chen* and Lihui Wang*, Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer. Cell Death & Disease, 2019, 10(6):400.中科院分区二区,IF:6.304

8.Lina Jia#,Hun Seok Lee#,Chun Fu Wu,Juthika Kundu,Sang Gyu Park,Ryong Nam Kim,Li-Hui Wang,Özgür Cem Erkin,Jong-Sun Choi,Seoung Wan Chae,Ho Bin Yang,Yoon-La Choi,Young Kee Shin*, SMAD4suppresses AURKA-induced metastatic phenotypes via degradation of AURKA in a TGFβ-independent manner. Molecular Cancer Research, 2014, 12(12):1779.中科院分区二区,IF:4.380